Back to search
FDAFDA · Food and drugs·Recall number D-0866-2016

OCTREOTIDE ACETATE INJECTION, 50 mcg (base)/mL (0.05 mg/mL), 1 mL Single Dose Vial, Rx only, Manufactured by Fresenius Kabi USA, LLC, Schaumburg, IL 60173, NDC 63323-365-01.

Published June 1, 2016 · Recall initiated: May 4, 2016

Summary

FDA records drug Class II recall D-0866-2016, published June 1, 2016 and initiated May 4, 2016. Recalling firm: Fresenius Kabi USA, LLC; Status: Terminated; Reported quantity: 355,150 vials; Lot: Lot # 6108322; Exp. 04/16 Lot # 6108824; Exp. 07/16. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impuities/Degradation Specifications

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Fresenius Kabi USA, LLC
Distributor
Nationwide and Puerto Rico.
Lot
Lot # 6108322; Exp. 04/16 Lot # 6108824; Exp. 07/16
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was OCTREOTIDE ACETATE INJECTION, 50 mcg (base)/mL (0.05 mg/mL), 1 mL Single Dose Vial, Rx only, Manufactured by Fresenius Kabi USA, LLC, Schaumburg, IL 60173, NDC 63323-365-01. recalled?

Yes. FDA published recall D-0866-2016 on June 1, 2016. Reported hazard: Failed Impuities/Degradation Specifications

What should I do if I have this product?

Voluntary: Firm initiated · Letter